Pins Justaret

Researchers are evaluating the effectiveness and safety of colchicine and non-enteric coated aspirin, used alone or together, to improve heart-related outcomes in high-risk adults aged 55 to 80 with type 2 diabetes. This study focuses on preventing major cardiovascular events such as heart attacks, strokes, and urgent hospitalizations in patients who have no prior history of coronary artery disease but possess other risk factors. Participants will be randomly assigned to one of four groups receiving either colchicine, aspirin, both drugs, or placebos. Aspirin is given as a 40 mg non-enteric-coated tablet twice daily, while colchicine is taken as a 0.5 mg tablet once daily. Those who cannot take aspirin will only be assigned to colchicine or its placebo groups. The study lasts up to 60 months, during which cardiovascular events and cognitive function using MoCA scores will be monitored. During the study, participants will undergo regular assessments to track cardiovascular events including heart attacks, stroke, cardiac arrest, atrial fibrillation, heart failure hospitalizations, and coronary procedures. Researchers will also evaluate cognitive function yearly. Safety checks and follow-up visits occur throughout the 5-year period to monitor the participants health and treatment adherence. The primary outcome is the time to the first major cardiovascular event after starting the study medications.

Fever is a common reason for children aged 3 months to 15 years to visit healthcare providers. It can be hard to tell if the fever is caused by a viral or bacterial infection just by examining the child, which sometimes requires additional tests like measuring C-reactive protein CRP. This study looks at using a capillary medical device to measure CRP directly in primary care to help reduce unnecessary referrals to emergency rooms and labs, improving care for febrile children and easing healthcare system burdens. The study compares two groups one using capillary CRP measurement with the ACTIM-CRP device and a control group without this intervention. Children are randomly assigned to these groups during their primary care visit when they have a fever that meets specific duration and severity conditions. The study runs from September 2025 to June 2027 and focuses on referral rates and other outcomes related to care pathways for febrile children. Participants will be involved in the study during their initial consultation and followed up for up to seven days to monitor referrals, antibiotic prescriptions, satisfaction of both general practitioners and parents, fever duration, and cost impacts. Data on complementary tests and healthcare usage will also be collected to understand the effects of using capillary CRP testing in primary care. The study aims to improve the efficiency and quality of care for children with fever.